Foghorn Therapeutics Posts $0.80 Q3 GAAP EPS, $83.5 Million Revenue
Image: TokenPost
Foghorn Therapeutics Inc. reported third-quarter GAAP earnings per share of $0.80 and revenue of $83.5 million, while research and development expenses declined from a year earlier. That was $1.2 million below the $20 million recorded in the three months ended Sept. 30, 2025. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Read the full story on TokenPostBeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.
